Study Complete
Sponsor ID
20130102

Single-Ascending Dose study of AMG 333 in healthy subjects and subjects with migraines

Sponsor ID
20130102
Clinicaltrials.gov ID
NCT01953341
EUCTIS ID
N/A
EudraCT ID
N/A

Study Details

The primary purpose of this study is to determine whether AMG 333 is safe and well tolerated in healthy subjects and subjects with migraines. As part of the secondary objectives, this study will characterize the pharmacokinetic (PK) profile of AMG 333, as well as characterize the effect of AMG 333 on the cold pressor test (CPT)-induced increase in blood pressure after single oral doses in healthy subjects and subjects with migraines

Additional Study Details

Phase
Phase 1
Product
AMG 333
Type
Interventional
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment
74
Additional Study Details

Protocol Summary

Primary Outcome Measures

Primary

Timeframe: Up to 29 days

Primary

Timeframe: Up to 29 days

Secondary Outcome Measures

Secondary Outcome Measures

Timeframe: Up to 29 Days

Secondary

Timeframe: Up to 29 days

Secondary Outcome Measures

Timeframe: Up to 29 Days

Secondary Outcome Measures

Timeframe: Up to 29 Days

Study Documents

Study Synopsis
Available Language(s): English

Locations

Location
Status
Contact Us
Location
Research Site
Salt Lake City, UT, United States, 84106
Status
Recruiting